Literature DB >> 24100264

Profibrotic effect of miR-33a with Akt activation in hepatic stellate cells.

Zhuo-Jian Li1, Pai-Huai Ou-Yang, Xing-Peng Han.   

Abstract

MicroRNAs (miRNAs) attract more attention in the pathophysiology of liver fibrosis and miR-33a has been previously demonstrated as involved in the regulation of cholesterol and lipid metabolism. Transforming growth factor-beta1 (TGF-β1) is generally accepted to be the main stimulating factor in the hepatic stellate cells (HSCs) activation, which plays an important role in hepatic fibrosis. However, the involvement and underlying mechanism of miR-33a and its role in TGF-β1-induced hepatic fibrogenesis remains unknown. Here, we investigate the role of miR-33a in the activation of immortalized human HSCs, Lx-2 cells. Our findings have shown that the expression of miR-33a with its host gene sterol regulatory element-binding protein 2 (SREBP2) was more highly expressed in activation of Lx-2 cells than in quiescent cells. The expression of miR-33a on TGF-β1-induced HSCs activation may be modulated via the activation of PI3K/Akt pathway. In addition, miR-33a significantly correlated with TGF-β1-induced expression of α1 (I) collagen (Col1A1) and α-SMA in HSCs. Bioinformatics analyses predict that peroxisome proliferator activated receptor-alpha (PPAR-α) is the potential target of miR-33a. We further found that anti-miR-33a significantly increases target gene PPAR-α mRNA and protein level, suggesting that miR-33a involved in HSCs function might be modulated by targeting PPAR-α. Finally, our results indicate that the expression of miR-33a increased with the progression of liver fibrosis. These results suggested that anti-miR-33a inhibit activation and extracellular matrix production, at least in part, via the activation of PI3K/Akt pathway and PPAR-α and anti sense of miR-33a may be a novel potential therapeutic approach for treating hepatic fibrosis in the future.
© 2013.

Entities:  

Keywords:  Hepatic stellate cells; PI3K/Akt; PPAR-α; TGF-β1; miR-33a; α-smooth muscle actin

Mesh:

Substances:

Year:  2013        PMID: 24100264     DOI: 10.1016/j.cellsig.2013.09.018

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  21 in total

1.  miR-33a levels in hepatic and serum after chronic HBV-induced fibrosis.

Authors:  Chuan-Feng Huang; Cheng-Chao Sun; Fang Zhao; Ya-Dong Zhang; De-Jia Li
Journal:  J Gastroenterol       Date:  2014-08-26       Impact factor: 7.527

2.  The mechanisms of HSC activation and epigenetic regulation of HSCs phenotypes.

Authors:  Agata Page; Derek A Mann; Jelena Mann
Journal:  Curr Pathobiol Rep       Date:  2014-09-27

3.  The peripheral CB1 receptor antagonist JD5037 attenuates liver fibrosis via a CB1 receptor/β-arrestin1/Akt pathway.

Authors:  Siwei Tan; Huiling Liu; Bilun Ke; Jie Jiang; Bin Wu
Journal:  Br J Pharmacol       Date:  2020-03-03       Impact factor: 8.739

4.  MicroRNA-370 Attenuates Hepatic Fibrogenesis by Targeting Smoothened.

Authors:  Cui-Hua Lu; Qian-Ru Hou; Long-Fei Deng; Chen Fei; Wen-Ping Xu; Qin Zhang; Kai-Ming Wu; Bei-Fang Ning; Wei-Fen Xie; Xin Zhang
Journal:  Dig Dis Sci       Date:  2015-02-17       Impact factor: 3.199

Review 5.  Delivery and targeting of miRNAs for treating liver fibrosis.

Authors:  Virender Kumar; Ram I Mahato
Journal:  Pharm Res       Date:  2014-09-04       Impact factor: 4.200

6.  miR-144 regulates transforming growth factor-β1 iduced hepatic stellate cell activation in human fibrotic liver.

Authors:  Zhiyong Liu; Jian Yi; Rong Ye; Jianping Liu; Qing Duan; Junqi Xiao; Fengen Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-04-01

Review 7.  The role of miRNAs in the regulation of inflammatory processes during hepatofibrogenesis.

Authors:  Sanchari Roy; Fabian Benz; Tom Luedde; Christoph Roderburg
Journal:  Hepatobiliary Surg Nutr       Date:  2015-02       Impact factor: 7.293

Review 8.  Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies.

Authors:  Giovanni Musso; Maurizio Cassader; Roberto Gambino
Journal:  Nat Rev Drug Discov       Date:  2016-01-22       Impact factor: 84.694

9.  Adiponectin inhibits hepatic stellate cell activation by targeting the PTEN/AKT pathway.

Authors:  Pradeep Kumar; Reben Raeman; Daniel M Chopyk; Tekla Smith; Kiran Verma; Yunshan Liu; Frank A Anania
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-08-08       Impact factor: 5.187

10.  Epigenetic Regulation of Myofibroblast Phenotypes in Fibrosis.

Authors:  Thu Elizabeth Duong; James S Hagood
Journal:  Curr Pathobiol Rep       Date:  2018-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.